Rockwell Medical, Inc.

Is Rockwell Medical, Inc. technically bullish or bearish?

As of August 13, 2025, Rockwell Medical, Inc. is in a mildly bearish trend, with mixed technical indicators and significant underperformance compared to the S&P 500, showing a year-to-date return of -34.80% versus the S&P's 12.22%.

As of 13 August 2025, the technical trend for Rockwell Medical, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a combination of indicators. The MACD shows a mildly bullish signal on both weekly and monthly time frames, while the RSI indicates bearish conditions on both time frames. The Bollinger Bands reflect a mildly bullish stance weekly but bearish monthly. Moving averages are mildly bearish on a daily basis, and Dow Theory shows a mildly bearish trend weekly with no trend monthly. <BR><BR>In terms of performance, the stock has underperformed the S&P 500 across multiple periods, with a year-to-date return of -34.80% compared to the S&P 500's 12.22%, and a one-year return of -66.92% versus 17.14% for the benchmark.

How big is Rockwell Medical, Inc.?

As of Jun 18, Rockwell Medical, Inc. has a market capitalization of 31.23 million and reported net sales of 97.72 million with a net profit of -0.56 million for the latest four quarters. Shareholder's funds were 32.59 million, and total assets were 59.21 million.

As of Jun 18, Rockwell Medical, Inc. has a market capitalization of 31.23 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 97.72 million for the latest four quarters, while the net profit for the same period was -0.56 million.<BR><BR>As of Dec 24, the shareholder's funds amounted to 32.59 million, and the total assets were reported at 59.21 million.

What does Rockwell Medical, Inc. do?

Rockwell Medical, Inc. is a biopharmaceutical company focused on treating end-stage renal disease and chronic kidney disease, with recent net sales of $19 million and a market cap of $31.23 million. The company is currently operating at a loss, with a net profit of -$2 million.

Overview:<BR>Rockwell Medical, Inc. is a biopharmaceutical company focused on treating end-stage renal disease and chronic kidney disease, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 19 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -2 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 31.23 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.21 <BR>Return on Equity: -1.76% <BR>Price to Book: 0.99<BR><BR>Contact Details:<BR>Address: 30142 WIXOM ROAD, WIXOM MI: 48393 <BR>Tel: 1 248 9609009 <BR>Website: https://www.rockwellmed.com/

Should I buy, sell or hold Rockwell Medical, Inc.?

Who are in the management team of Rockwell Medical, Inc.?

As of March 2022, the management team of Rockwell Medical, Inc. includes Mr. John McLaughlin (Independent Chairman), Dr. Russell Ellison (President and CEO), and Independent Directors Mr. John Cooper, Mr. Robert Radie, and Mr. Mark Ravich. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Rockwell Medical, Inc. includes the following individuals:<BR><BR>- Mr. John McLaughlin, who serves as the Independent Chairman of the Board.<BR>- Dr. Russell Ellison, who is the President, Chief Executive Officer, and a Director.<BR>- Mr. John Cooper, who is an Independent Director.<BR>- Mr. Robert Radie, who is also an Independent Director.<BR>- Mr. Mark Ravich, who serves as an Independent Director.<BR><BR>This team is responsible for guiding the company's strategic direction and operations.